All Drug Discovery articles – Page 23
-
ArticleUsing clinical genomics and AI in drug development to elevate success
How are clinical genomics and AI transforming drug development? Industry experts reveal how these technologies improve target identification, patient stratification, and trial design to drive higher success rates.
-
NewsScientists identify key protein fuelling autoimmune attacks
Mass General Brigham researchers found granzyme K (GZMK) drives inflammation in autoimmune diseases, opening new possibilities for targeted treatments.
-
NewsUC Davis researchers achieve total synthesis of ibogaine
UC Davis researchers achieve a breakthrough in synthesising ibogaine, enabling safer drug development for addiction and depression treatment.
-
ArticleNew study links type 2 diabetes to accelerated cognitive decline
Study reveals how type 2 diabetes accelerates cognitive decline by damaging white matter in the brain. Sam Hashemi at Prenuvo explains how advanced AI and whole-body MRI technology are opening new possibilities for early intervention.
-
NewsAzenta's BioArc Ultra powers UK research
UK Biocentre has significantly expanded its sample storage capacity with the addition of Azenta's BioArc Ultra, adding space for 16 million more samples to support vital health research.
-
NewsRestoring the gut: VE303's strategy for C. diff relief
A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C. difficile infection, detailing its impact on the gut microbiome and immune response.
-
ArticlePromising Alzheimer’s drug earns FDA fast-track designation
Posdinemab, being investigated by Johnson & Johnson, has received FDA fast-track status. Hear from Dr Fiona Elwood as she explains how Johnson & Johnson’s precision medicine approach could transform Alzheimer’s treatment.
-
NewsAI designs peptides for 'undruggable' diseases
A new AI-powered approach is tackling the challenge of 'undruggable' diseases by designing peptides that can bind to and destroy previously untreatable proteins.
-
NewsITM-11 boosts survival in neuroendocrine tumour trial
A new targeted radiotherapy offers hope for patients with rare neuroendocrine tumours, demonstrating a significant improvement in progression-free survival in a key clinical trial.
-
NewsFirst patient enrolled in fostamatinib trial for sickle cell disease
Rigel Pharmaceuticals has announced the enrolment of the first patient in a Phase I trial evaluating fostamatinib for sickle cell disease.
-
ArticleNew study explores safer antidepressants for pregnant women
A new study suggests that targeting serotonin in the gut, rather than the brain, could lead to antidepressants with fewer side effects.
-
NewsNew study shows CGM data can predict diabetes complications
UVA researchers found that continuous glucose monitor data can predict nerve, eye, and kidney damage in type 1 diabetes.
-
NewsThe Michael J Fox Foundation for Parkinson’s Research awards grant to Grifols for pioneering study
Grifols has received a $21 million grant from The Michael J. Fox Foundation to fund a pioneering study aimed at identifying early biomarkers for Parkinson's disease (PD).
-
NewsUVA’s computer models target antibiotics to combat resistance
Researchers at the University of Virginia School of Medicine have developed computer models to create more targeted antibiotics. This approach aims to fight antibiotic resistance by focusing on specific bacteria in different parts of the body, reducing the reliance on broad-spectrum antibiotics.
-
NewsBio-Rad introduces mixed-mode resin for biomolecule purification
Bio-Rad has launched Nuvia wPrime 2A Media, a scalable resin designed for biomolecule purification in research and biotherapeutic applications.
-
ArticleObstacles and innovations of macrocyclic drug development
Macrocycles outperform traditional therapeutics on several fronts, yet they account for just four percent of FDA-approved drugs. Colleagues Ann E Cleves and Ajay N Jain from Optibrium Ltd explain why we can expect to see this number increase in the coming years.
-
NewsLB Pharmaceuticals announces positive schizophrenia trial data
LB Pharmaceuticals announced positive Phase II results for LB-102, showing significant symptom improvement in schizophrenia with a favourable safety profile.
-
ArticleScientific workflow for hypothesis testing in drug discovery: Part 2 of 3
In part two of the step-by-step scientific workflow for drug discovery series, Dr Raminderpal Singh and Nina Truter describe the functions of the workflow previously outlined and include key considerations.
-
NewsNew painless vaccine technology targets viruses
Learn how Kindeva and Emervax are advancing vaccine delivery with painless, needle-free technology designed to improve accessibility and uptake worldwide.
-
NewsInnovative lupus treatment under investigation at Virginia Tech
A Virginia Tech student is investigating new treatments for lupus, an autoimmune disease that affects millions worldwide.